-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 D4JOjjVa4ZvN2Ad+kEZvxRSODNP4oXI5h/M3Q+5zj7jYb3rvuyoZ5K6cfWF3jq8C
 BFcpPydLujnkXIPlm8cxyA==

<SEC-DOCUMENT>0000842023-08-000018.txt : 20080805
<SEC-HEADER>0000842023-08-000018.hdr.sgml : 20080805
<ACCEPTANCE-DATETIME>20080805091638
ACCESSION NUMBER:		0000842023-08-000018
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20080805
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20080805
DATE AS OF CHANGE:		20080805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TECHNE CORP /MN/
		CENTRAL INDEX KEY:			0000842023
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				411427402
		STATE OF INCORPORATION:			MN
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17272
		FILM NUMBER:		08989840

	BUSINESS ADDRESS:	
		STREET 1:		614 MCKINLEY PL N E
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
		BUSINESS PHONE:		6123798854

	MAIL ADDRESS:	
		STREET 1:		614 MCKINLEY PLACE NE
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>k8q.txt
<DESCRIPTION>8-K
<TEXT>
                      SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549

                                FORM 8-K

                              CURRENT REPORT

                  PURSUANT TO SECTION 13 OR 15(d) OF THE
                     SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported): August 5, 2008

                            TECHNE CORPORATION
             (Exact Name of Registrant as Specified in Charter)


       Minnesota                     0-17272             41-1427402
(State or Other Jurisdiction       (Commission         I.R.S. Employer
of Incorporation)                  File Number)      Identification No.)

                614 Mckinley Place NE
                   Minneapolis, MN                       55413
       (Address of Principal Executive Offices)       (Zip Code)

     Registrant's telephone number, including area code:  (612) 379-8854

                              Not Applicable
      (Former Name or Former Address, if changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any
of the following provisions:

/ /   Written communications pursuant to Rule 425 under the Securities Act
      17 CFR 230.425)

/ /   Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)

/ /   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

/ /   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))


<PAGE>



Item 2.02  Results of Operations and Financial Condition

A copy of the press release issued by Techne Corporation on August 5,
2008, describing the results of operations for the quarter and fiscal year
ended June 30, 2008 and its financial condition as of June 30, 2008,
is attached hereto as Exhibit 99.1.

Segment information for Techne Corporation for the quarter and fiscal year
ended June 30, 2008 which has been included on Techne Corporation's
website (www.techne-corp.com), is attached hereto as Exhibit 99.2.

The information in this Form 8-K and the Exhibits attached hereto shall not
be deemed "filed" for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the "Exchange Act"), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference
in any filing under the Securities Act of 1933 or the Exchange Act, except as
expressly set forth by specific reference in such filing.


Item 9.01 Financial Statements and Exhibits

     (d) Exhibits

         99.1 Press Release dated August 5, 2008.

         99.2 Segment information for the quarter and fiscal year ended
              June 30, 2008.






                            SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Dated: August 5, 2008                TECHNE CORPORATION
                                      By: /s/ Thomas E. Oland
                                      ---------------------------
                                      Name: Thomas E. Oland
                                      Title: President and Chief
                                        Executive Officer



                          EXHIBIT INDEX

    Exhibit No. Description
    ----------- -----------
       99.1     Press release of Techne Corporation dated August 5, 2008.

       99.2     Segment information for Techne Corporation for the quarter
                and fiscal year ended June 30, 2008.

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>release.txt
<DESCRIPTION>EARNINGS RELEASE DATED AUGUST 5, 2008
<TEXT>


                            TECHNE CORPORATION
                   RELEASES UNAUDITED FOURTH QUARTER RESULTS
                            FOR FISCAL YEAR 2008

Minneapolis/August 5, 2008/--Techne Corporation's (NASDAQ: TECH) consolidated
net earnings for the quarter ended June 30, 2008 increased 18.9% to $27.3
million or $.70 per diluted share compared with $22.9 million or $.58 per
diluted share for the quarter ended June 30, 2007.  For the fiscal year ended
June 30, 2008, Techne's consolidated net earnings increased 21.7% to $103.6
million or $2.64 per diluted share compared with $85.1 million or $2.15 per
diluted share for the fiscal year ended June 30, 2007.

Net earnings as a percentage of net sales improved to 40.2% for the fiscal
year ended June 30, 2008 from 38.1% in the fiscal year ended June 30, 2007.
The improvement in net earnings was mainly due to increased consolidated net
sales. The favorable impact on consolidated net earnings of the change in
exchange rates used to convert foreign currencies (primarily British pound
sterling and Euros) to U.S. dollars was $296,000 ($.008 per diluted share)
for the quarter and $1.3 million ($.034 per diluted share) for the fiscal
year ended June 30, 2008.

Consolidated net sales for the quarter and fiscal year ended June 30, 2008
were $67.8 million and $257.4 million, respectively. This was an increase of
16.0% and 15.2% from the quarter and fiscal year ended June 30, 2007,
respectively. Consolidated net sales were favorably affected by the strength
of foreign currencies as compared to the U.S. dollar. Excluding the effect of
changes in foreign currency exchange rates, consolidated net sales increased
12.1% and 12.3% for the quarter and fiscal year ended June 30, 2008,
respectively, from the comparable prior year periods.

Biotechnology net sales, which include sales by R&D Systems' Biotechnology
Division, R&D Systems China and BiosPacific, were $42.5 million and $165.7
million for the quarter and fiscal year ended June 30, 2008, increases of
11.6% and 13.0%, respectively, from the quarter and fiscal year ended June
30, 2007.  This improvement was primarily the result of increased volume,
including shipments to diagnostic customers.  Increased sales to diagnostic
customers positively effected Biotechnology net sales in the second and third
quarters of fiscal 2008.  The timing of diagnostic customer sales is not
predictable and these sales increases are not necessarily indicative of future
sales.  Excluding sales to diagnostic customers, Biotechnology net sales
increased 12.4% for the fiscal year ended June 30, 2008 from the comparable
prior year period.

R&D Europe's net sales for the quarter and fiscal year ended June 30, 2008
were $21.0 million and $75.7 million, increases of 30.0% and 22.6%,
respectively, from the same prior-year periods.  R&D Europe's net sales
increased 16.0% and 12.2% for the quarter and fiscal year ended June 30,
2008 when measured at currency rates in effect in the comparable prior periods.

Hematology net sales for the quarter and fiscal year ended June 30, 2008
were $4.2 million and $16.0 million, increases of 1.9% and 6.1%, respectively,
compared to the quarter and fiscal year ended June 30, 2007. The increase for
the fiscal year was mainly due to increased volume sales to several OEM
customers during the third quarter of the fiscal year.

Consolidated gross margins were 79.5% for both the quarter and fiscal year
ended June 30, 2008, compared to 78.3% and 79.1% for the quarter and fiscal
year ended June 30, 2007, respectively. The gross margin improvement resulted
from higher gross margins in Europe due to favorable exchange rates and changes
in sales mix as a result of higher sales growth in the Biotechnology Division
as compared to the sales growth in the lower margin Hematology Division.  This
improvement was partially offset by lower gross margins generated from high
volume sales to diagnostic customers, particularly in the second and third
quarters of the fiscal year.

Selling, general and administrative expenses for the quarter and fiscal year
ended June 30, 2008 increased $1.1 million (14.6%) and $5.7 million (18.6%),
respectively, from the same prior year periods. These increases include wage
and salary increases and the hiring of additional marketing and
administrative personnel to support the Company's sales growth.  Selling,
general and administrative expenses for the quarter ended June 30, 2008 also
increased from the same prior year period due to increased profit sharing and
bonuses of $841,000.  Selling, general and administrative expenses for the
fiscal year ended June 30, 2008 also increased because of additional profit
sharing and bonuses of $2.0 million, increased legal fees of $837,000, R&D
China selling, general and administrative expenses of $552,000, and the change
in foreign currency exchange rates used to convert British pounds to U.S.
dollars of $311,000.

The effective tax rates for both the quarter and fiscal year ended June 30,
2008 were 32.7% as compared to effective tax rates of 32.9% and 34.0% for
the quarter and fiscal year ended June 30, 2007, respectively. Fiscal year
2008 rates were positively impacted by changes in state apportionment
estimates.  Without significant business developments, the Company expects
its fiscal 2009 effective income tax rate to range from approximately 33.0%
to 34.0%.

In November 2007, the Company's Board of Directors authorized the repurchase
 and retirement of up to $150 million of the Company's common stock.  The
Company repurchased approximately 140,000 shares of its common stock during
the fourth quarter of fiscal 2008 for approximately $9.4 million.  During
fiscal 2008, the Company repurchased approximately 899,000 shares of its
common stock for approximately $58.7 million.

Forward Looking Statements:

This earnings release contains forward-looking statements within the
meaning of the Private Litigation Reform Act.  These statements,
including the Company's expectations as to and income tax rates,
involve risks and uncertainties that may affect the actual results of
operations. The following important factors, among others, have affected and,
in the future, could affect the Company's actual results: the introduction
and acceptance of new biotechnology and hematology products, the levels and
particular directions of research by the Company's customers, the impact of
the growing number of producers of biotechnology research products and
related price competition, the retention of hematology OEM and proficiency
survey business, the impact of currency exchange rate fluctuations, and the
costs and results of research and product development efforts of the Company
and of companies in which the Company has invested or with which it has
formed strategic relationships.


For additional information concerning such factors, see the Company's annual
report on Form 10-K and quarterly reports on Form 10-Q as filed with the
Securities and Exchange Commission.  We undertake no obligation to update or
revise any forward-looking statements we make in this release due to new
information or future events.  Investors are cautioned not to place undue
emphasis on these statements.

                     *  *  *  *  *  *  *  *  *  *  *  *

Techne Corporation has two operating subsidiaries:  Research and Diagnostic
Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems
Europe, Ltd. (R&D Europe) of Abingdon, England.  R&D Systems is a specialty
manufacturer of biological products.  R&D Systems has two subsidiaries,
BiosPacific, Inc. (BiosPacific), located in Emeryville, California and R&D
Systems China Co. Ltd., (R&D China), located in Shanghai, China.  BiosPacific
is a worldwide supplier of biologics to manufacturers of in vitro diagnostic
systems and immunodiagnostic kits. R&D China and R&D Europe distribute
biotechnology products.

Contact:  Greg Melsen, Chief Financial Officer
          Kathy Backes, Controller
          612) 379-8854



                      TECHNE CORPORATION
              CONSOLIDATED STATEMENTS OF EARNINGS
                 (In thousands, except per share data)
                              (Unaudited)

                                       QUARTER ENDED    FISCAL YEAR ENDED

                                     6/30/08  6/30/07   6/30/08  6/30/07
                                     -------  -------  --------  -------
Net sales                            $67,769  $58,425  $257,420 $223,482
Cost of sales                         13,888   12,697    52,889   46,667
                                     -------  -------  -------- --------
Gross margin                          53,881   45,728   204,531  176,815
                                     -------  -------  -------- --------
Operating expenses:
 Selling, general and administrative   8,986    7,839    36,715   30,965
 Research and development              5,812    5,014    22,394   20,082
 Amortization of intangible assets       282      404     1,135    1,614
                                     -------  -------  -------- --------
      Total operating expenses        15,080   13,257    60,244   52,661
                                     -------  -------  -------- --------
Operating income                      38,801   32,471   144,287  124,154
Other expense (income):
 Interest expense                         --       --        --    1,083
 Interest income                      (2,783)  (2,565)  (12,188)  (8,434)
 Other non-operating expense, net      1,079      894     2,644    2,574
                                     -------  -------  -------- --------
      Total other income              (1,704)  (1,671)   (9,544)  (4,777)
                                     -------  -------  -------- --------
Earnings before income taxes          40,505   34,142   153,831  128,931
Income taxes                          13,248   11,218    50,273   43,820
                                     -------  -------  -------- --------
Net earnings                         $27,257  $22,924  $103,558 $ 85,111
                                     =======  =======  ======== ========
Earnings per share:
 Basic                               $  0.70  $  0.58  $   2.65 $   2.16
 Diluted                             $  0.70  $  0.58  $   2.64 $   2.15
Weighted average common
 shares outstanding:
 Basic                                38,665   39,444    39,139   39,406
 Diluted                              38,788   39,555    39,247   39,513




                          TECHNE CORPORATION
                       CONSOLIDATED BALANCE SHEETS
                             (In thousands)
                                (Unaudited)

                                                  6/30/08     6/30/07
                                                 --------    --------
ASSETS
Cash and equivalents                             $166,992    $135,485
Short-term available-for-sale investments          39,353      29,289
Trade accounts receivable                          31,747      29,559
Other receivables                                   1,585       1,407
Inventory                                           9,515       8,757
Other current assets                                9,241       8,341
                                                 --------    --------
  Current assets                                  258,433     212,838
Available-for-sale investments                     87,384      91,433
Property and equipment, net                       101,722      91,535
Goodwill and intangible assets, net                29,032      30,167
Other non-current assets                           30,798      28,871
                                                 --------    --------
  Total assets                                   $507,369    $454,844
                                                 ========    ========
LIABILITIES
Current liabilities                              $ 20,239    $ 17,193
Stockholders' equity                              487,130     437,651
                                                 --------    --------
  Total liabilities and equity                   $507,369    $454,844
                                                 ========    ========








</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>segment608.txt
<DESCRIPTION>SEGMENT RESULTS
<TEXT>
                                            SEGMENT INFORMATION
                                   TECHNE CORPORATION AND SUBISIDARIES
                               (in thousands of $'s, except per share data)
<TABLE>
<CAPTION>
                                                                           Increase (Decrease)
                                      Fiscal 2008                           From Fiscal 2007
                 ------------------------------------------------ --------------------------------------
                  First  Second  Third   Fourth          Percent   First  Second  Third   Fourth
                 Quarter Quarter Quarter Quarter   YTD   of Sales Quarter Quarter Quarter Quarter   YTD
                 ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
<S>              <C>     <C>     <C>     <C>     <C>     <C>      <C>     <C>     <C>     <C>     <C>
Sales             57,987  62,142  69,522  67,769 257,420    100%    5,636   9,633   9,325   9,344 33,938
Cost of sales     12,104  12,751  14,146  13,888  52,889     21%      867   2,037   2,127   1,191  6,222
                 ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Gross margin      45,883  49,391  55,376  53,881 204,531     79%    4,769   7,596   7,198   8,153 27,716

Gross margin
 percentage        79.1%   79.5%   79.7%   79.5%   79.5%

SG&A expense       8,090  10,645   8,994   8,986  36,715     14%    1,023   1,815   1,765   1,147  5,750
R&D expense        5,181   5,562   5,839   5,812  22,394      9%      326     518     670     798  2,312
Amortization
 expense             288     282     283     282   1,135      -      (115)   (122)   (120)   (122)  (479)
Interest expense       0       0       0       0       0      -      (268)   (815)      0       0 (1,083)
Interest income   (2,998) (3,252) (3,155) (2,783)(12,188)    (5%)  (1,322) (1,296)   (918)   (218)(3,754)
Other non-opera-
 ting ex., net       569     573     423   1,079   2,644      1%       84     145    (344)    185     70
                 ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
                  11,130  13,810  12,384  13,376  50,700     19%     (272)    245   1,053   1,790  2,816
                 ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Earnings before
 income taxes     34,753  35,581  42,992  40,505 153,831     60%    5,041   7,351   6,145   6,363 24,900
Income taxes      11,681  11,942  13,402  13,248  50,273     20%    1,600   2,375     448   2,030  6,453
                 ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
                  23,072  23,639  29,590  27,257 103,558     40%    3,441   4,976   5,697   4,333 18,447
                 ======= ======= ======= ======= ======= ======== ======= ======= ======= ======= ======
Diluted earnings
per share            .58     .60     .76     .70    2.64
Weighted average
 diluted shares
 outstanding      39,587  39,497  39,108  38,788  39,247

</TABLE>


                                        BIOTECHNOLOGY  (1)
                                       (in thousands of $'s)

<TABLE>
<CAPTION>
                                                                           Increase (Decrease)
                                      Fiscal 2008                           From Fiscal 2007
                 ------------------------------------------------ --------------------------------------
                  First  Second  Third   Fourth          Percent   First  Second  Third   Fourth
                 Quarter Quarter Quarter Quarter   YTD   of Sales Quarter Quarter Quarter Quarter   YTD
                 ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
<S>              <C>     <C>     <C>     <C>     <C>     <C>      <C>     <C>     <C>     <C>     <C>
Sales             45,328  46,576  52,912  49,995 194,811    100%    3,707   6,503   6,710   5,207 22,127
Intersegment
 sales            (6,447) (7,433) (7,822) (7,446)(29,148)            (748)   (786)   (750)   (794)(3,078)
                 ------- ------- ------- ------- -------          ------- ------- ------- ------- ------
                  38,881  39,143  45,090  42,549 165,663            2,959   5,717   5,960   4,413 19,049

Cost of sales      8,997   9,612  10,709  10,247  39,565     20%      515   1,929   1,668     670  4,782
Intersegment
 sales            (6,174) (7,430) (7,755) (7,738)(29,097)            (650)   (995)   (608) (1,059)(3,312)
                 ------- ------- ------- ------- -------          ------- ------- ------- ------- ------
                   2,823   2,182   2,954   2,509  10,468             (135)    934   1,060    (389) 1,470

Gross margin      36,058  36,961  42,136  40,040 155,195     80%    3,094   4,783   4,900   4,802 17,579

Gross margin
 percentage        80.2%   79.4%   79.8%   79.5%   79.7%

SG&A expense       4,624   5,534   5,257   5,566  20,981     10%      611     870   1,091     949  3,521
R&D expense        5,002   5,368   5,640   5,622  21,632     11%      327     514     669     789  2,299
Amortization
 expense             288     282     283     282   1,135      1%     (115)   (122)   (120)   (122)  (479)
Interest, net     (1,257) (1,309) (1,285)   (988) (4,839)    (2%)    (662)   (587)   (444)     43 (1,650)
Exchange loss/
 (gain)               34      12      (5)    389     430      --       34      12      (5)    389    430
                 ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
                   8,691   9,887   9,890  10,871  39,339     20%      195     687   1,191   2,048  4,121
                 ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Pretax result     27,367  27,074  32,246  29,169 115,856     60%    2,899   4,096   3,709   2,754 13,458
                 ======= ======= ======= ======= ======= ======== ======= ======= ======= ======= ======
</TABLE>

(1) Includes R&D Systems' Biotechnology Division,
BiosPacific, Inc. and R&D China


                                        R&D SYSTEMS EUROPE
                                  (in thousands of British pounds)

<TABLE>
<CAPTION>
                                                                           Increase (Decrease)
                                      Fiscal 2008                           From Fiscal 2007
                 ------------------------------------------------ --------------------------------------
                  First  Second  Third   Fourth          Percent   First  Second  Third   Fourth
                 Quarter Quarter Quarter Quarter   YTD   of Sales Quarter Quarter Quarter Quarter   YTD
                 ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
<S>              <C>     <C>     <C>     <C>     <C>     <C>      <C>     <C>     <C>     <C>     <C>
Sales              7,605   9,301  10,180  10,565  37,651    100%      735   1,450   1,326   2,411  5,922
Cost of sales      3,455   4,053   4,392   4,486  16,386     44%      170     287     301     689  1,447
                 ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Gross margin       4,150   5,248   5,788   6,079  21,265     56%      565   1,163   1,025   1,722  4,475

Gross margin
 percentage        54.6%   56.4%   56.9%   57.5%   56.5%

SG&A expense       1,114   1,276   1,163   1,253   4,806     13%       40      40      88     140    308
Interest income     (683)   (773)   (762)   (740) (2,958)    (8%)    (273)   (293)   (220)   (145)  (931)
Exchange gain        (96)    (81)   (230)     (9)   (416)    (2%)    (174)    (17)   (252)    (15)  (458)
                 ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
                     335     422     171     504   1,432      3%     (407)   (270)   (384)    (20)(1,081)
                 ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Pretax result      3,815   4,826   5,617   5,575  19,833     53%      972   1,433   1,409   1,742  5,556
                 ======= ======= ======= ======= ======= ======== ======= ======= ======= ======= ======
</TABLE>



                                       R&D SYSTEMS EUROPE
                                      (in thousands of $'s)

<TABLE>
<CAPTION>
                                                                           Increase (Decrease)
                                      Fiscal 2008                           From Fiscal 2007
                 ------------------------------------------------ --------------------------------------
                  First  Second  Third   Fourth          Percent   First  Second  Third   Fourth
                 Quarter Quarter Quarter Quarter   YTD   of Sales Quarter Quarter Quarter Quarter   YTD
                 ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
<S>              <C>     <C>     <C>     <C>     <C>     <C>      <C>     <C>     <C>     <C>     <C>
Sales             15,449  19,027  20,226  21,033  75,735    100%    2,522   3,770   2,823   4,854 13,969
Cost of sales      7,020   8,293   8,726   8,922  32,961     44%      839     974     686   1,381  3,880
                 ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Gross margin       8,429  10,734  11,500  12,111  42,774     56%    1,683   2,796   2,137   3,473 10,089

Gross margin
 percentage        54.6%   56.4%   56.9%   57.6%   56.5%

SG&A expense       2,262   2,599   2,311   2,495   9,667     13%      242     194     199     276    911
Interest income   (1,387) (1,576) (1,514) (1,472) (5,949)    (8%)    (616)   (643)   (447)   (298)(2,004)
Exchange gain       (198)   (165)   (457)    (17)   (837)    (2%)    (345)    (39)   (499)    (36)  (919)
                 ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
                     677     858     340   1,006   2,881      3%     (719)   (488)   (747)    (58)(2,012)
                 ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Pretax result      7,752   9,876  11,160  11,105  39,893     53%    2,402   3,284   2,884   3,531 12,101
                 ======= ======= ======= ======= ======= ======== ======= ======= ======= ======= ======
</TABLE>


                                        HEMATOLOGY
                                     (in thousands of $'s)

<TABLE>
<CAPTION>
                                                                           Increase (Decrease)
                                      Fiscal 2008                           From Fiscal 2007
                 ------------------------------------------------ --------------------------------------
                  First  Second  Third   Fourth          Percent   First  Second  Third   Fourth
                 Quarter Quarter Quarter Quarter   YTD   of Sales Quarter Quarter Quarter Quarter   YTD
                 ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
<S>              <C>     <C>     <C>     <C>     <C>     <C>      <C>     <C>     <C>     <C>     <C>
Sales              3,657   3,972   4,206   4,187  16,022   100%       155     146     542      77    920
Cost of sales      2,261   2,276   2,466   2,457   9,460    59%       163     129     381     199    872
                 ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Gross margin       1,396   1,696   1,740   1,730   6,562    41%        (8)     17     161    (122)    48

Gross margin
 percentage        38.2%   42.7%   41.4%   41.3%   41.0%

SG&A expense         467     487     489     560   2,003    12%        69      48      58     138    313
R&D expense          179     194     199     190     762     5%        (1)      4       1       9     13
Interest, net       (120)   (125)   (123)    (93)   (461)   (3%)      (39)    (30)    (12)     43    (38)
                 ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
                     526     556     565     657   2,304    14%        29      22      47     190    288
                 ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Pretax result        870   1,140   1,175   1,073   4,258    27%       (37)     (5)    114    (312)  (240)
                 ======= ======= ======= ======= ======= ======== ======= ======= ======= ======= ======

</TABLE>


                                     CORPORATE AND OTHER (2)
                                       (in thousands of $'s)
<TABLE>
<CAPTION>
                                                                        Increase (Decrease)
                                            Fiscal 2008                  From Fiscal 2007
                       --------------------------------------- --------------------------------------
                       First  Second  Third   Fourth          First  Second  Third   Fourth
                       Quarter Quarter Quarter Quarter   YTD   Quarter Quarter Quarter Quarter   YTD
                       ------- ------- ------- ------- ------- ------- ------- ------- ------- ------
<S>                    <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>
Interest income            234     242     233     230     939       5      36      15       6     62
Rental income               67     111      91     135     404    (232)   (130)     36      44   (282)
                       ------- ------- ------- ------- ------- ------- ------- ------- ------- ------
                           301     353     324     365   1,343    (227)    (94)     51      50   (220)

SG&A expense               737   2,025     937     365   4,064     101     703     417    (216) 1,005
Interest expense            --      --      --      --      --    (268)   (815)     --      -- (1,083)
Other-Building
 expenses                  544     600     633     538   2,315      34      51     114     (96)   103
Other-Equity
 Investment losses         256     237     343     304   1,140     129      (9)     82     (28)   174
                       ------- ------- ------- ------- ------- ------- ------- ------- ------- ------
                         1,537   2,862   1,913   1,207   7,519      (4)    (70)    613    (340)   199
                       ------- ------- ------- ------- ------- ------- ------- ------- ------- ------
Pretax result           (1,236) (2,509) (1,589)   (842) (6,176)   (223)    (24)   (562)    390   (419)
                       ======= ======= ======= ======= ======= ======= ======= ======= ======= ======

</TABLE>

(2) Unallocated corporate expenses and Techne's share
of losses by Hemerus Medical, LLC and Nephromics, LLC.
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
